Short answer
RUNX1 genetic testing is considered when a person or family has lifelong easy bruising, prolonged bleeding, platelet dysfunction or low platelets, and a pattern that raises concern for RUNX1 familial platelet disorder with associated myeloid malignancies. The clinically meaningful result is a germline RUNX1 pathogenic variant, because that is what changes family risk and donor planning.
Why RUNX1 is different
| Feature | Why it matters | |
|---|---|---|
| Bleeding history | RUNX1-FPDMM can cause platelet dysfunction and bruising or bleeding. | Procedures may need hematology planning. |
| MDS or AML in a family | Myeloid malignancies are a key risk in the syndrome. | Surveillance and family testing may be discussed. |
| Platelet count may not tell the whole story | Counts can be low, borderline, or even normal in some carriers. | Function testing and family history still matter. |
| Transplant relevance | A related donor may share the familial variant. | Donor selection can change. |
What testing usually looks for
RUNX1 testing may use a single-gene test or a broader hereditary myeloid panel. GeneReviews and NCI describe missense, nonsense, splice-site, small insertion/deletion, and copy-number variants, so testing that includes deletion/duplication analysis can matter. Some families are better served by a broad panel when the platelet phenotype is not classic.
Why germline confirmation is different
Blood cancers complicate inherited testing because blood or marrow DNA can contain acquired cancer-related variants. If RUNX1 is found during a leukemia, MDS, or cytopenia workup, the care team may need genetic counseling and a validated germline specimen strategy before relatives or donors are tested.
What the result may change
A confirmed germline RUNX1 variant can affect procedures, bleeding precautions, family cascade testing, surveillance for MDS or AML, and whether a related stem-cell donor is appropriate. It can also help explain why platelet function may look abnormal even when the count is only mildly changed.
Questions to ask
- Was the RUNX1 result found on tumor sequencing, germline testing, or a hereditary hematologic malignancy panel?
- Does the family history include easy bruising, low platelets, MDS, AML, or unexplained blood cancers?
- Should relatives or potential stem-cell donors be tested before donor selection?
- What CBC, platelet function, marrow, or symptom surveillance is recommended by the hematology team?
FAQ
What does RUNX1 genetic testing look for?
It looks for germline RUNX1 pathogenic variants associated with familial platelet disorder with associated myeloid malignancies, a syndrome that can involve bleeding, low platelets or platelet dysfunction, and MDS or AML risk.
Can platelet counts be normal in RUNX1 families?
Yes. Platelet counts can be mildly low, normal, or only part of the picture. A bleeding history and platelet function pattern can still matter even when the count is not strikingly abnormal.
Why is germline confirmation important?
A RUNX1 finding on tumor sequencing may be somatic or germline. Confirming the variant in an appropriate non-tumor specimen is what determines inherited family risk.
Why do donor questions matter?
If a related stem-cell donor carries the same germline RUNX1 variant, that donor may not be a safe choice. Donor testing can change transplant planning.
What findings usually prompt testing?
Easy bruising, surgical bleeding, thrombocytopenia, abnormal platelet aggregation, or a family history of MDS, AML, or platelet disorder are common reasons to consider testing.
What if RUNX1 testing is negative?
A negative result lowers the chance that RUNX1 explains the pattern, but it does not rule out other hereditary platelet or myeloid-risk genes or acquired platelet problems.
Related guides: platelet function testing, CBC blood test, DDX41 genetic testing, and tumor genomic vs inherited genetic testing.